Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2018 Filed Nov 19, 2018 23:15 UTC |
Thomsen Jillian B.SVP & Chief Accounting Officer
|
SaleCommon Stock | 4,016 | $38.25 | $153,612.00 |
DisclosureSEC source: 0001209191-18-059297 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,249 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:14 UTC |
Nicholson JohnSVP & Chief Operating Officer
|
SaleCommon Stock | 5,982 | $38.25 | $228,811.50 |
DisclosureSEC source: 0001209191-18-059293 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,477 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:13 UTC |
Labrucherie Gil MSVP & Chief Financial Officer
|
SaleCommon Stock | 6,515 | $38.25 | $249,198.75 |
DisclosureSEC source: 0001209191-18-059290 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,544 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:14 UTC |
ROBIN HOWARD WDirector · President & CEO
|
SaleCommon Stock | 15,326 | $38.25 | $586,219.50 |
DisclosureSEC source: 0001209191-18-059295 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,141 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:12 UTC |
Hora ManinderSVP Pharma Dev & Mfg Ops
|
SaleCommon Stock | 4,694 | $38.25 | $179,545.50 |
DisclosureSEC source: 0001209191-18-059289 · doc4.xml · nonDerivative · entry 1 Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,029 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 6,968 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:11 UTC |
Doberstein Stephen KSVP & Chief Scientific Officer
|
SaleCommon Stock | 4,524 | $38.25 | $173,043.00 |
DisclosureSEC source: 0001209191-18-059288 · doc4.xml · nonDerivative · entry 1 Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,734 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 23:00 UTC |
Thomsen Jillian B.SVP & Chief Accounting Officer
|
GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057268 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,265 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest quarterly in substantially equal installments on November 15, 2020, February 15, 2021, May 15, 2021, and August 15, 2021, based on the reporting person's continued service with the Company. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:25 UTC |
WHITFIELD ROY ADirector
|
GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052912 · doc4.xml · derivative · entry 3 WHITFIELD ROY A · CIK 0000936728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:25 UTC |
WHITFIELD ROY ADirector
|
GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052912 · doc4.xml · nonDerivative · entry 1 WHITFIELD ROY A · CIK 0000936728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,750 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:24 UTC |
Lingnau LutzDirector
|
GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052911 · doc4.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:24 UTC |
Lingnau LutzDirector
|
GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052911 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:22 UTC |
GREER R SCOTTDirector
|
GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052909 · doc4.xml · derivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:22 UTC |
GREER R SCOTTDirector
|
GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052909 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,083 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:23 UTC |
KUEBLER CHRISTOPHER ADirector
|
GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052910 · doc4.xml · derivative · entry 2 KUEBLER CHRISTOPHER A · CIK 0001229877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:23 UTC |
KUEBLER CHRISTOPHER ADirector
|
GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052910 · doc4.xml · nonDerivative · entry 1 KUEBLER CHRISTOPHER A · CIK 0001229877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,250 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:21 UTC |
CHESS ROBERTDirector
|
GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052908 · doc4.xml · derivative · entry 2 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:21 UTC |
CHESS ROBERTDirector
|
GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052908 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,473 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:20 UTC |
Ajer Jeffrey RobertDirector
|
GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052907 · doc4.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:20 UTC |
Ajer Jeffrey RobertDirector
|
GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052907 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:19 UTC |
EASTHAM KARINDirector
|
GrantStock Option · Derivative | 17,000 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052906 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the three-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:19 UTC |
EASTHAM KARINDirector
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052906 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests over three years in equal annual installments beginning on September 27, 2018. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 23:32 UTC |
Lingnau LutzDirector
|
SaleCommon Stock | 9,000 | $56.98 | $512,820.00 |
DisclosureSEC source: 0001209191-18-052001 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $56.32 to $57.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 23:29 UTC |
Ajer Jeffrey RobertDirector
|
SaleCommon Stock | 6,750 | $56.76 | $383,130.00 |
DisclosureSEC source: 0001209191-18-051998 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.24 to $57.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 23:31 UTC |
CHESS ROBERTDirector
|
SaleCommon Stock | 4,500 | $56.81 | $255,645.00 |
DisclosureSEC source: 0001209191-18-051999 · doc4.xml · nonDerivative · entry 1 CHESS ROBERT · CIK 0001227886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,723 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $55.71 to $58.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:12 UTC |
GREER R SCOTTDirector
|
Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-18-049963 · doc4.xml · derivative · entry 3 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2019-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:12 UTC |
GREER R SCOTTDirector
|
SaleCommon Stock | 10,000 | $67.39 | $673,900.00 |
DisclosureSEC source: 0001209191-18-049963 · doc4.xml · nonDerivative · entry 2 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,333 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $65.81 to $67.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 23:12 UTC |
GREER R SCOTTDirector
|
Exercise / conversionCommon Stock | 10,000 | $5.14 | $51,400.00 |
DisclosureSEC source: 0001209191-18-049963 · doc4.xml · nonDerivative · entry 1 GREER R SCOTT · CIK 0001211703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 23:32 UTC |
WINGER DENNIS LDirector
|
Exercise / conversionStock Option · Derivative | 15,000 | $14.26 Strike: $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · derivative · entry 7 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 23:32 UTC |
WINGER DENNIS LDirector
|
SaleCommon Stock | 15,000 | $60.30 | $904,500.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 4 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 23:32 UTC |
WINGER DENNIS LDirector
|
Exercise / conversionCommon Stock | 15,000 | $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 3 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:32 UTC |
WINGER DENNIS LDirector
|
Exercise / conversionStock Option · Derivative | 15,000 | $14.26 Strike: $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · derivative · entry 6 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2018-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:32 UTC |
WINGER DENNIS LDirector
|
SaleCommon Stock | 15,000 | $59.62 | $894,300.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 2 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $59.61 to $59.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:32 UTC |
WINGER DENNIS LDirector
|
Exercise / conversionCommon Stock | 15,000 | $14.26 | $213,900.00 |
DisclosureSEC source: 0001209191-18-047854 · doc4.xml · nonDerivative · entry 1 WINGER DENNIS L · CIK 0001222645 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made for stock options scheduled to expire on September 14, 2018. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:46 UTC |
Nicholson JohnSVP & Chief Operating Officer
|
Disposition to issuerCommon Stock | 8,137 | $58.40 | $475,200.80 |
DisclosureSEC source: 0001209191-18-047242 · doc4.xml · nonDerivative · entry 2 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,459 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:47 UTC |
Thomsen Jillian B.SVP & Chief Accounting Officer
|
Disposition to issuerCommon Stock | 4,883 | $58.40 | $285,167.20 |
DisclosureSEC source: 0001209191-18-047243 · doc4.xml · nonDerivative · entry 2 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,265 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:45 UTC |
Labrucherie Gil MSVP & Chief Financial Officer
|
Disposition to issuerCommon Stock | 8,207 | $58.40 | $479,288.80 |
DisclosureSEC source: 0001209191-18-047241 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,059 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:44 UTC |
Hora ManinderSVP Pharma Dev & Mfg Ops
|
Disposition to issuerCommon Stock | 5,946 | $58.40 | $347,246.40 |
DisclosureSEC source: 0001209191-18-047240 · doc4.xml · nonDerivative · entry 2 Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,723 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 6,968 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:44 UTC |
ROBIN HOWARD WDirector · President & CEO
|
Disposition to issuerCommon Stock | 20,389 | $58.40 | $1,190,717.60 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,467 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:43 UTC |
Doberstein Stephen KSVP & Chief Scientific Officer
|
Disposition to issuerCommon Stock | 6,701 | $58.40 | $391,338.40 |
DisclosureSEC source: 0001209191-18-047237 · doc4.xml · nonDerivative · entry 2 Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,258 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:46 UTC |
Nicholson JohnSVP & Chief Operating Officer
|
GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047242 · doc4.xml · derivative · entry 3 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F4 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F5 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F6 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:46 UTC |
Nicholson JohnSVP & Chief Operating Officer
|
GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047242 · doc4.xml · nonDerivative · entry 1 Nicholson John · CIK 0001420766 · SVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,596 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:47 UTC |
Thomsen Jillian B.SVP & Chief Accounting Officer
|
GrantStock Option · Derivative | 26,250 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047243 · doc4.xml · derivative · entry 3 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-12-14 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F6 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:47 UTC |
Thomsen Jillian B.SVP & Chief Accounting Officer
|
GrantCommon Stock | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047243 · doc4.xml · nonDerivative · entry 1 Thomsen Jillian B. · CIK 0001433457 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,148 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · balance_after: This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 4,170 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:45 UTC |
Labrucherie Gil MSVP & Chief Financial Officer
|
GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047241 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F6 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:45 UTC |
Labrucherie Gil MSVP & Chief Financial Officer
|
GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047241 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,266 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:44 UTC |
Hora ManinderSVP Pharma Dev & Mfg Ops
|
GrantStock Option · Derivative | 37,500 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047240 · doc4.xml · derivative · entry 3 Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2025-12-14 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F6 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:44 UTC |
Hora ManinderSVP Pharma Dev & Mfg Ops
|
GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047240 · doc4.xml · nonDerivative · entry 1 Hora Maninder · CIK 0001443159 · SVP Pharma Dev & Mfg Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,669 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · balance_after: This number includes 6,968 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:44 UTC |
ROBIN HOWARD WDirector · President & CEO
|
GrantStock Option · Derivative | 151,250 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · derivative · entry 7 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,250 Underlying: Common Stock · 151,250 shares Expires 2025-12-14 F6 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F7 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F8 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:44 UTC |
ROBIN HOWARD WDirector · President & CEO
|
GrantCommon Stock | 60,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047238 · doc4.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,856 F3 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:43 UTC |
Doberstein Stephen KSVP & Chief Scientific Officer
|
GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047237 · doc4.xml · derivative · entry 3 Doberstein Stephen K · CIK 0001480111 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F4 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F5 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F6 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.